- Maravai LifeSciences Holdings, Inc. is a leading life sciences company developing and providing critical products for new drug development, diagnostics, novel vaccines, and human disease research.
- Maravai LifeSciences operates three core businesses including Nucleic Acid Production, Biologics Safety Testing, and Protein Detection offering a compelling technological advantage and superiority in terms of sensitivity and specificity.
- Maravai is in a strong financial position with FYE 2020 revenues of $284M (+99% y/y) alongside a positive net income of $89M and positive cash flow from operations of $152M.
- Management guidance for 2021 outlines again strong revenue growth of +146% reaching ~$700M with an EBITDA target of $460M outlining strong margin expansion, albeit with a lower EPS target of $1.08/share.
- In summary, the author projects Maravai LifeSciences Holdings, Inc. as a "buy" at a 2-year price target of ~$52/share (+22% upside).
For further details see:
Maravai LifeSciences: The Future Beyond Covid Vaccines